MipSalus ApS

MipSalus ApS is a pioneering biotechnology company dedicated to developing innovative treatments for severe, rare amino acid metabolism disorders. Focused on improving patient outcomes, MipSalus ApS is committed to making a significant impact on healthcare through its groundbreaking research and development efforts.

The company's leading drug candidate, Phelimin, targets Phenylketonuria (PKU), offering patients the potential to enjoy a more normal diet and lifestyle. Phelimin, an oral, non-systemic drug, has received orphan drug designations from both the EMA and FDA, underscoring its promise in addressing this unmet medical need. MipSalus ApS’s medicinal products are based on their proprietary Molecular Imprinted Polymers (MIP) technology platform, employing MIPs to selectively bind pathogenic amino acids within the gastrointestinal tract.

Located at Agern Allé 3, Hørsholm, DK-2970, DK, MipSalus ApS operates with a streamlined core organization, fostering close collaborations with private subcontractors and universities to ensure optimal efficiency and flexibility. MipSalus ApS is poised to continue its advancements in biotechnology, further solidifying its commitment to healthcare innovation and patient well-being. We invite the manager of MipSalus ApS to create a customized and exclusive company showcase and product listing on our platform.